MABp1 IN HIDRADENITIS SUPPURATIVA REFRACTORY TO ADALIMUMAB
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder. Although adalimumab is
recently licensed for moderate to severe HS, many cases fail to respond or relapse during
treatment. Favorable outcomes from a recently conducted double-blind randomized clinical
study on the efficacy of anakinra, one interleukin(IL)-1alpha blocker, in hidradenitis
suppurativa (HS), led to validate the efficacy of MABp1, a true human antiIL-1α antibody in
these cases.